Photo via TIME

A Personalized Cancer Vaccine Lowers Melanoma Recurrence by 42%

Read the original at TIME ↗
Cite

Park, A. (2026, October 22). A Personalized Cancer Vaccine Lowers Melanoma Recurrence by 42%. TIME. https://time.com/article/2026/10/22/moderna-merck-immunotherapy-lowers-melanoma-recurrence/

Dated from the outlet's own feed. Check the original for its byline.

TIME · collected 2026-10-23 · by Alice Park

Quick Summary

Moderna and Merck announced on October 22 that their customized cancer vaccine for late-stage melanoma reduces recurrence or death risk by 42% over two years compared to standard treatment. The study involved more than 1,130 patients who had tumors surgically removed and were then given either the intismeran vaccine (along with Keytruda) or a placebo plus Keytruda. Intismeran uses mRNA technology to help immune cells recognize specific tumor proteins, enhancing their ability to fight cancer alongside Keytruda's role in removing brakes on immune cell activity. The results closely matched earlier findings and showed the therapy’s effectiveness starts around six months after beginning treatment.
Written by AI on 2026-10-23, from this article's own text only (the story summary below draws on all the coverage).
See how they differ ↓

AI analysis

Story summary

Moderna and MSD developed intismeran, a personalized mRNA-based vaccine, which when combined with Keytruda (pembrolizumab) reduced the risk of melanoma recurrence or death by 42% in patients two years after surgery. The trial included over 1,100 participants with high-risk melanoma that had been surgically removed. Intismeran targets up to 34 tumor neoantigens specific to each patient's tumor, enhancing the immune system’s ability to fight cancer. Although results are promising and could mark a turning point in personalized cancer treatment, longer-term studies are needed to confirm long-term benefits and impact on overall survival rates. The vaccine is currently experimental and not available on healthcare systems like NHS yet. Similar approaches are being tested for other cancers including kidney, bladder, and lung cancer. The detailed findings were initially scheduled to be presented at the European Society of Medical Oncology Congress but were released ahead of time due to data leaks. Lead researcher Professor Georgina Long from Melanoma Institute Australia described the results as "phenomenal" and potentially transformational for cancer treatment. Independent experts also view the outcome positively, though they emphasize the need for extended follow-up studies to establish definitive benefits in patient longevity.

Written for “mRNA Cancer Vaccine Breakthrough For Melanoma” on 2026-11-21, grounded in this article and the 7 other(s) covering the same event.

How they differ

8 outlets covered “mRNA Cancer Vaccine Breakthrough For Melanoma”.

What each outlet says

One AI summary per outlet of its latest article on this story, written from that article alone and checked against it. Open the article for the outlet's own words.

TimeThis outlet23 Oct

Moderna and Merck announced on October 22 that their customized cancer vaccine for late-stage melanoma reduces recurrence or death risk by 42% over two years compared to standard treatment. The study involved more than 1,130 patients who had tumors surgically removed and were then given either the intismeran vaccine (along with Keytruda) or a placebo plus Keytruda. Intismeran uses mRNA technology to help immune…

A Personalized Cancer Vaccine Lowers Melanoma Recurrence by 42% (this article)
The Independent22 Oct

ModernA’s mRNA cancer vaccine combined with Merck's immunotherapy reduced melanoma recurrence or death risk by 42%, according to a Phase 3 clinical trial involving over 1,100 patients. The study also showed a 38% reduction in the spread of cancer and revealed that 82.2% of patients receiving both treatments remained cancer-free after two years compared to 70% for those treated with Keytruda alone. ModernA plans to…

mRNA cancer vaccine slashes melanoma death or recurrence risk by 42% →
Toronto Star22 Oct

Moderna and Merck released results from a major study showing that an mRNA-based cancer vaccine called intismeran significantly reduces by 42% the risk of melanoma returning two years after surgery. The personalized vaccine, which targets unique gene mutations in each patient's tumor, was administered alongside standard post-surgery treatment to over 1,100 people with high-risk melanoma. At the end of the trial, 82%…

A novel mRNA cancer vaccine helps reduce the chances of melanoma patients' tumors returning →
Daily Mail23 Oct

Professor Georgina Long led a world-first cancer vaccine trial that significantly reduced the risk of melanoma recurrence or death by 42% compared to patients treated with only pembrolizumab (Keytruda). The study, involving 1,137 participants across 157 global sites, tested an individualised mRNA vaccine called intismeran, developed by Moderna and MSD. This breakthrough could revolutionize cancer treatment…

World-first cancer vaccine slashes death risk in stunning findings led by Aussie scientist →
ABC News (AU)23 Oct

Researchers led by Australia have developed a world-first cancer vaccine that significantly reduces the risk of melanoma recurrence by 42 percent, according to phase 3 trial results. The study, set to be published in the New England Journal of Medicine, involved 1,137 patients and compared personalized mRNA-based vaccines combined with immunotherapy against immunotherapy alone. The treatment identifies unique…

Australia at the heart of 'transformational' cancer vaccine breakthrough →
BBC23 Oct

A new personalized cancer vaccine, when combined with an existing immunotherapy drug called Keytruda, has shown significant promise in reducing the recurrence and spread of melanoma by 42% and 38%, respectively, over two years. This trial involved more than 1,100 patients who had their tumors surgically removed. The vaccine, named Intismeran, uses mRNA technology similar to that used in some COVID vaccines, tailored…

First personalised cancer vaccine cuts risk of disease returning in major trial →
Show 2 more outlets
Evening Standard23 Oct

A large trial has shown that a personalized mRNA cancer vaccine for melanoma reduces the risk of recurrence or death by 42% when used with immunotherapy. The study involved over 1,100 high-risk melanoma patients who had surgery to remove their tumors. This vaccine works by targeting specific markers on each patient’s tumor and activating an immune response against these unique cancer mutations. The combination…

World’s first mRNA cancer jab for melanoma cuts risk of death by 42% →
CBC23 Oct

Moderna and Merck released results from a major study showing their mRNA-based personalized cancer vaccine, intismeran, significantly reduces the risk of melanoma recurrence by 42% when used in conjunction with an existing treatment. The vaccine is tailored to each patient based on unique genetic mutations found in their tumor, leveraging mRNA technology similar to that used in COVID-19 vaccines. Dr. Hussein Tawbi…

A novel mRNA cancer vaccine helps cut the chances of melanoma tumor recurrence in major study →

Where they agree and split

Framing

How the first headlines put it

Stated as fact7
The headlines (7)

mRNA cancer vaccine slashes melanoma death or recurrence risk by 42% The Independent · stated as fact

A novel mRNA cancer vaccine helps reduce the chances of melanoma patients' tumors returning Toronto Star · stated as fact

A Personalized Cancer Vaccine Lowers Melanoma Recurrence by 42% Time · stated as fact

World-first cancer vaccine slashes death risk in stunning findings led by Aussie scientist Daily Mail · stated as fact

Australia at the heart of 'transformational' cancer vaccine breakthrough ABC News (Australia) · stated as fact

First personalised cancer vaccine cuts risk of disease returning in major trial BBC · stated as fact

World’s first mRNA cancer jab for melanoma cuts risk of death by 42% Evening Standard · stated as fact

The full story: what happened, how it changed, and all 8 articles →

Compared with similar articles

This article reads unscored and hedges 11% of its claims. Each row says how that neighbour differs.
CBC News
Hedges 3 of 46 claims Outlet record 72/100
The Independent
Hedges 0 of 16 claims Outlet record 59/100
Daily Mail
Hedges 1 of 10 claims Outlet record 69/100
BBC News
Hedges 2 of 28 claims Outlet record 65/100
Evening Standard
Hedges 1 of 25 claims Outlet record 64/100
Toronto Star
Hedges 3 of 35 claims Outlet record 64/100
ABC News (AU)
Hedges 3 of 34 claims Outlet record 67/100

Story

mRNA Cancer Vaccine Breakthrough For Melanoma
Health · 8 article(s) covering the same event. Compare every outlet's account →
How this article was measured signals, leaning charts, publisher record, byline, topics and claims

Signals How these are calculated →

Claims extracted
28
sentences that state something as happening or true
Uncertain
11%
3 of 28 hedged ("reportedly", "may", "according to")
Leaning
not political
takes no side on a contested political question
Publisher signals
60/100
TIME's corrections and hedging, across everything collected from it. Not a measure of accuracy.
Outlets on this story
8
Health
Same framing elsewhere
1
articles that frame the event the way this one does
Analyzed 2026-10-23 · how these are computed

How this is being covered How these are calculated →

Article leaning vs. publisher reliability
Source leaning vs. consistency

Publisher

TIME · 1078 article(s) · 2 correction(s) detected
Running correction rate · 2 correction(s)

Who wrote this

Alice Park
9 article(s) here · 1 carrying a prediction
A calculation that takes into account a person’s weight and height, BMI is supposed to reflect how much excess fat a person might be carrying and give doctors a sense of a patient's risk for obesity-related health conditions.
2026-11-13 · assertive framing · Why BMI Is Not the Best Measure of Health
Asundexian, which will be sold under the brand name Sunharbo, is a daily pill that is the first to target a specific factor in the blood-clotting process that can contribute to stroke.
On a crisp October day, the CEO of Moderna, of COVID-vaccine fame, is sitting in his glass-walled office in the company’s headquarters in Cambridge, Mass., weeks before encouraging results from the company’s first mRNA cancer vaccine would become public.
2026-11-12 · assertive framing · The Next Chapter of mRNA
The results will be presented at the European Society of Medical Oncology meeting in Madrid on Oct. 24.
Immune-based treatments for cancer have become the biggest new advance in tackling tumors, and the latest approval could make a big difference for some people with rectal cancer.
The scientists used a modified version of a reprogramming strategy that earned a Nobel Prize in 2012 for turning mature, adult cells back to an embryonic-like state from which they could become any of the cells in the body—including healthy new versions of diseased or older cells.
Since each has specific receptors in the body and brain, targeting all three may be contributing to the more potent effects on weight for people with diabetes than drugs that target GLP-1 alone, like Ozempic and Wegovy (semaglutide), or GLP-1 and GIP together, as Mounjaro and Zepbound (tirzepatide) do.
In a new study published in Science, researchers report that for some of those cases, an inherited genetic mutation might be involved.
Also by Alice Park
The Next Chapter of mRNA
2026-11-12 · TIME
Nothing else under this byline is closely related to this article, so these are simply their most recent.
All 9 articles by Alice Park →

Topics

European Society of Medical Oncology Keytruda Madrid Merck Moderna

Subjects

Moderna ORG · 5× Merck ORG · 3× Berman PERSON · 2× David Berman PERSON · 1× European Society of Medical Oncology ORG · 1× Madrid GPE · 1×

Narrative

“I was surprised by the fact that the results replicated the Phase 2 [study] so closely,” says Dr. David Berman, chief development officer at Moderna, referring to an earlier stage study the companies released in June that the combination lowered the risk of cancer returning or death by 49% over a year.
framing: assertive · carried by 1 article(s) · first seen 2026-10-23
The results will be presented at the European Society of Medical Oncology meeting in Madrid on Oct. 24.
2026-10-23 · TIME
A Personalized Cancer Vaccine Lowers Melanoma Recurrence by 42% · assertive framing

Claims (28 extracted, 3 hedged)

Moderna and Merck reported on Oct. 22 that a customized cancer vaccine for people with late-stage melanoma can reduce the risk of cancer recurrence or death over two years by 42% compared to current treatment. asserted
vaccine → report → treatment
The results will be presented at the European Society of Medical Oncology meeting in Madrid on Oct. 24. asserted
results → present → Oct.
The study involved more than 1,130 people with Stage 2B to Stage 4 melanoma, all of whom had their tumors surgically removed. asserted
tumors → involve → whom
Some were then randomly assigned to have a cancer vaccine custom-made after their tumors had been genetically sequenced. asserted
tumors → assign → vaccine
They received that vaccine, called intismeran, once every three weeks for up to nine doses, along with Keytruda, a checkpoint inhibitor, every six weeks for up to nine cycles, for about a year. asserted
They → receive → year
Others were randomly assigned to receive a placebo vaccine and Keytruda. Intismeran, developed jointly by Moderna and Merck, represents a new way to harness the immune system in cancer, by training immune cells to recognize 34 specific proteins on tumor cells. asserted
Intismeran → assign → cells
The mRNA coding for these proteins, or antigens, are encased in a lipid particle in a similar way to Moderna’s COVID vaccine, which used mRNA from the COVID virus’ spike protein. asserted
which → cod → protein
Using this mRNA approach, once cells start making the foreign proteins coded for by the mRNA, the immune system sees them as intruders and mounts a response against them—and the latest data show that the approach works not just against viral proteins but also against those found on tumors. asserted
approach → use → tumors
Keytruda contributes a key part of the response by removing the brakes that keep immune cells from recognizing and attacking tumor cells because they originate from normal "self" cells. asserted
they → contribute → cells
“I was surprised by the fact that the results replicated the Phase 2 [study] so closely,” says Dr. David Berman, chief development officer at Moderna, referring to an earlier stage study the companies released in June that the combination lowered the risk of cancer returning or death by 49% over a year. asserted
combination → surprise → year
That study also reported that the therapy lowered the risk of the cancer spreading to other sites by 59% compared to the checkpoint inhibitor alone. asserted
cancer → report → inhibitor
“This Phase 3 [study] included a much broader population, so the hypothesis was that the treatment effect would be harder to see. asserted
effect → include → population
There was a lot of suspicion going in that these results would not be as good as those in the Phase 2. asserted
results → be → Phase
But the fact that they reproduced almost exactly what we saw initially in the Phase 2 blew my mind.” asserted
we → reproduce → mind
The companies report that the effect seems to start six months into the therapy—an important insight in understanding how immune-based approaches may work in cancer. uncertain
approaches → report → cancer
“We think it’s because the immune system takes time to be activated,” says Berman. asserted
Berman → think → time
That includes making sure that immune cells like T cells, which are critical to recognizing and controlling cancer, have time to learn to detect tumors. asserted
which → include → tumors
Berman says these results could also help to explain why only about 30% of cancer patients respond to the checkpoint inhibitors, a powerful new tool in cancer that allows immune cells to see tumors rather than thinking they are "self" cells and therefore not foreign. uncertain
they → say → tumors
“This shows us that in a significant percentage of patients, the checkpoint inhibitors are not doing anything because the immune system hasn’t even been educated to recognize the cancer cells,” he says of the potential role that the mRNA-based intismeran may play. uncertain
intismeran → show → that
“That’s where we now need to focus—on how to better educate the immune system. asserted
we → ’ → system
It’s a big leap, a big piece of information, that there is now another way to educate the immune system to recognize cancer. asserted
It → ’ → cancer
Moderna and Merck are studying the intismeran-Keytruda pairing in other cancer types in nine other studies, such as pancreatic and gastric cancer, as well as in three late-stage trials of non-small cell lung cancer. asserted
Moderna → study → cancer
They are also exploring the role of using intismeran alone in an early study in lung cancer. asserted
They → explore → cancer
Traditionally, personalized therapies have not been practical as medical treatment because of their high cost and long timeline to develop. asserted
therapies → develop → cost
But Berman is confident that the bespoke process of making an individualized mRNA cancer vaccine for each patient is both scalable and potentially affordable. asserted
process → make → patient
“We have scaled down the technical footprint and have plans to scale up [the program] to look at different tumors,” he says. asserted
he → scale → tumors
“The nice thing about the [mRNA] system is that it’s purely enzymatic, so no cell cultures need to be grown.” asserted
cultures → ’ → system
Another advantage of using mRNA is its speed—scientists at Moderna can develop a customized vaccine based on a patient’s tumor within weeks—critical for any patient with cancer. asserted
scientists → use → cancer
Give feedback · no sign-in needed

No sign-in needed for now. Your note is sent without a name, so it cannot be answered.

History Support